How this page evolved

Every published version is kept. Each entry shows what changed and why. Earlier versions can be restored by moderators, but only if the material they rely on is still available.

1. Revision 3Oct 4, 2026, 3:30 PMLiveAI-organised, reviewed

   Added a new randomized trial of Saccharomyces boulardii for antibiotic-associated diarrhea (100 patients; 7.8% vs 71.4% AAD) and a real-world Chinese cohort in IBS-D/IBS-M (IBS-SSS -95 vs -60), plus a pediatric IBS meta-analysis noted as outside the adult scope. Updated the antibiotic-diarrhea and IBS sections, takeaways, guidance, and uncertainty to reflect these concrete numbers.

   • · The main finding was rewritten.
   • · Updated “Antibiotic-associated diarrhea: the strongest signal”.
   • · Updated “Irritable bowel syndrome: a real but uneven benefit”.
   • · 3 new sources cited.
   • · The note on uncertainty changed.
   • · The key takeaways were revised.
   • · 1 new open question.
2. Revision 2Oct 3, 2026, 6:19 PMAI-organised, reviewed

   AI-prepared Starting Map from live research.

   • · First published version.